Deciphera Pharmaceuticals, Inc. (DCPH) reports first quarter loss, shortfall revenue estimates

Deciphera Pharmaceuticals, Inc. (DCPH) reported quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.55. For comparison, a year earlier the loss was $0.60 per share. These numbers have been adjusted for one-off items.

This quarterly report presented an earnings surprise of 5.45%. A quarter ago, it was expected that this company would post a loss of $0.58 per share when it actually produced a loss of $0.54, delivering a surprise of 6.90%.

The company has topped consensus EPS estimates four times over the last four quarters.

Deciphera Pharmaceuticals, which belongs to the Zacks Medical – Biomedical and Genetics industry, posted revenues of $45 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.15%. For comparison, revenues from the previous year amounted to $33.45 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the immediate share price movement based on the recently-released numbers and future earnings expectations will largely depend on management’s commentary on the earnings call.

Deciphera Pharmaceuticals shares are up about 57.3% year-to-date compared to the S&P 500 Index’s gain of 9.3%.

What’s next for Deciphera Pharmaceuticals?

While Deciphera Pharmaceuticals has outperformed the market this year, investors are wondering what’s next for the stock?

There are no simple answers to this key question, but one reliable measure that can help investors address this issue is the company’s earnings prospects. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of the earnings release, the estimate revision trend for Deciphera Pharmaceuticals is mixed. While the magnitude and direction of estimate revisions may change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) stock. Therefore, the company’s stock is expected to perform in line with the market in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the next quarters and the current fiscal year change in the coming days. The current consensus EPS estimate is -$0.55 on revenue of $48.39M for the coming quarter and -$2.16 on revenue of $198.39M for the current fiscal year.

Investors should be aware that the outlook for the industry may also have a significant impact on share prices. In terms of the Zacks Industry Rank, the Medical Biomedical and Genetics industry is currently in the top 34% of over 250 Zacks industries. Our research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another company in the same industry, Liquidia Technologies, Inc. (LQDA), has not yet released results for the quarter ending March 2024. Results are expected to be released on May 14.

The company is expected to report quarterly loss of $0.32 per share in the upcoming report, representing a year-over-year change of -77.8%. The consensus EPS estimate for the quarter has not changed over the last 30 days.

Liquidia Technologies, Inc. revenues are expected to be will amount to USD 4.31 million, which means a decrease of 4% compared to the same quarter last year.

Want the latest recommendations from Zacks Investment Research? Today you can download the top 7 stocks for the next 30 days. Click to get this free report

Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report

Liquidia Technologies, Inc. (LQDA): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research